LiDCO Group plc (AIM: LID), the cardiovascular monitoring company, is pleased to announce that Professor David Bennett, has joined its Clinical Advisory Board.

Professor Bennett was the Director of the Intensive Care Unit, St George’s Hospital for more than 25 years and is a member of the editorial board of Intensive Care Medicine and Critical Care. One of his main research interests has been the application of less invasive monitoring technologies to optimise cardiovascular physiology and thereby improve outcomes in critically ill patients. He was one of the investigators using LiDCO’s technology in the recently presented St George’s study entitled: ‘Early goal directed therapy reduces morbidity and length of hospital stay following high risk surgery.’

Dr Terry O'Brien, LiDCO's Chief Executive, commented:  “I am delighted to welcome Prof David Bennett to our Clinical Advisory Board. David is internationally renowned for his pioneering work on the application of less invasive cardiovascular monitoring to improve outcomes and reduce costs associated with the treatment of risk surgery patients.”

Prof David Bennett commented: "I am very pleased to be associated with LiDCO and their innovative technology which facilitates the rapid and accurate assessment of cardiac function. The use of this technology has allowed us to complete a post operative study in high risk surgery patients in whom the targeting of oxygen delivery has led to a 40% reduction in length of hospital stay"

Notes for Editors

About LiDCO Plc

LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. Use of LiDCO’s technology has been shown to significantly reduce the complications (particularly infections) and costs associated with major surgery The technology was invented in the Department of Applied Physiology based at St Thomas’ Hospital, London where the Company maintains a research base.

The Company’s manufacturing facility is in Hoxton, London and its current products are:

• LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume;

• LiDCO disposables: used in conjunction with the LiDCOplus Monitor accurately determine cardiac output in a minimally-invasive manner.

Distribution Network:

Following today’s announcement the Company has now achieved registration of its products in 13 markets in Europe, the USA, Brazil and Japan.  It sells direct to the NHS in the UK, and through a worldwide network of specialty critical care distributors.

Background to the recently published clinical trial: Better than standard care - (EGDT) improves outcome in high risk surgery patients:

The results of a major trial at St George’s Hospital, London using LiDCO’s minimally invasive monitoring technology were presented during the 25th International Symposium on Intensive Care and Emergency Medicine in Brussels (21st to 25th March). The results have revealed the following:

a) Savings in the cost of treating patients amounting to an average of £4,000 per patient.  Extrapolated nationally, this would equate to a saving of £500 million per annum for the NHS

b) The monetary saving (£248,000) - resulted from 640 hospital days saved for 62 patients, an average of more than 10 bed days per patient

c) The savings in cost and hospital days were associated with a significant reduction in medical complications (particularly infections – which were halved) through the use of LiDCO’s minimally invasive technology to improve tissue oxygen levels following surgery.